Avidity Biosciences, Inc. (RNA)
Market Cap | 2.11B |
Revenue (ttm) | 9.56M |
Net Income (ttm) | -212.22M |
Shares Out | 79.72M |
EPS (ttm) | -2.91 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 626,119 |
Open | 26.68 |
Previous Close | 25.58 |
Day's Range | 26.08 - 27.34 |
52-Week Range | 4.83 - 27.66 |
Beta | 0.77 |
Analysts | Strong Buy |
Price Target | 38.29 (+44.76%) |
Earnings Date | May 14, 2024 |
About RNA
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial;... [Read more]
Financial Performance
In 2023, RNA's revenue was $9.56 million, an increase of 3.64% compared to the previous year's $9.22 million. Losses were -$212.22 million, 22.0% more than in 2022.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for RNA stock is "Strong Buy." The 12-month stock price forecast is $38.29, which is an increase of 44.76% from the latest price.
News
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...
Avidity Biosciences to Participate in Upcoming Investor Conferences
SAN DIEGO , March 27, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...
Avidity Biosciences Honors Rare Disease Day®
SAN DIEGO , Feb. 29, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C...
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
Funding from new and existing investors, including Adage Capital Partners LP, Boxer Capital, Casdin Capital, LLC, Farallon, Janus Henderson Investors, RA Capital Management, RTW Investments, Wellingto...
Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights
Avidity is on-track to initiate global Phase 3 HARBOR™ trial of AOC 1001 for DM1 in mid-2024 Company to share first-look at long-term efficacy and safety data from MARINA-OLE™ trial in people living w...
Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth
Avidity plans to initiate global Phase 3 HARBOR ™ trial of AOC 1001 for DM1 mid-2024 Company to report data from all three ongoing clinical programs in 2024 -- AOC 1001 data for DM1 in Q1, AOC 1020 d...
Avidity Stock Soars on Collaboration Deal With Bristol Myers
Bristol Myers has agreed to pay Avidity $60 million in cash and will also purchase about $40 million of Avidity common stock at $7.88 a share.
Avidity's stock soars on news of expanded collaboration with Bristol Myers that includes potential to receive up to $2.2 billion in milestone payments
Avidity Biosciences Inc. RNA said Tuesday it's expanding its cardiovascular collaboration with Bristol Myers Squibb Co. BMY in a deal that will see Avidity receive $100 million upfront with the potent...
Avidity Biosciences to Participate in Upcoming Investor Conference
SAN DIEGO , Nov. 21, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C...
Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights
Avidity reported new positive AOC 1001 data at World Muscle Society (WMS) Congress in October demonstrating consistent improvement in multiple additional functional endpoints and favorable long-term s...
Avidity Biosciences Announces Upcoming Presentations at 28th Annual Congress of the World Muscle Society
SAN DIEGO , Sept. 26, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...
Avidity Biosciences Joins with Patient Communities to Raise Awareness During National Muscular Dystrophy Awareness Month as it Advances Three Muscular Dystrophy Clinical Programs
Avidity supports World Duchenne Awareness Day, International Myotonic Dystrophy Awareness Day, FSHD Society Walk & Roll to Cure FSHD and Global Genes Week in RARE Avidity joins with MDF community lead...
Avidity Biosciences Announces Upcoming Presentations at 2023 Myotonic Dystrophy Foundation Annual Conference
SAN DIEGO , Aug. 31, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C...
Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights
Advancing three clinical development programs – DM1, DMD, FSHD - with data anticipated from each program over the next 12 months SAN DIEGO , Aug. 8, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nas...
Avidity Biosciences Joins with Patients, Caregivers and Healthcare Providers Globally to Support World Facioscapulohumeral Muscular Dystrophy (FSHD) Day
Avidity is currently enrolling participants in the Phase 1/2 FORTITUDE™ study of AOC 1020 for the treatment of FSHD Company anticipates data from a preliminary assessment in half of the participants i...
Avidity Biosciences Announces Upcoming Presentations at the 30th Annual FSHD Society International Research Congress
SAN DIEGO , June 8, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Co...
Avidity Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights
Positive topline data from AOC 1001 Phase 1/2 MARINA™ trial demonstrated functional improvement, disease modification and favorable safety and tolerability profile in people living with myotonic dystr...
Avidity Biosciences Announces Positive Topline Data from AOC 1001 Phase 1/2 MARINA™ Trial Demonstrating Functional Improvement, Disease Modification and Favorable Safety and Tolerability Profile in People Living with Myotonic Dystrophy Type 1
SAN DIEGO, April 27, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avidity Biosciences, Inc. - RNA
NEW YORK , April 19, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avidity Biosciences, Inc. ("Avidity" or the "Company") (NASDAQ: RNA). Such investors are advis...
Avidity Biosciences Announces Upcoming Presentations at the 75th American Academy of Neurology Annual Meeting
SAN DIEGO, April 17, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C...
Avidity's stock falls after sharing additional data about partial clinical hold
Shares of Avidity Biosciences Inc. RNA, +0.55% fell about 3.0% in premarket trading on Thursday after the company said a partial clinical hold on its experimental treatment for adults with myotonic dy...
Avidity Biosciences Announces Upcoming Presentations at 2023 MDA Clinical & Scientific Conference
SAN DIEGO , March 13, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...
Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Highlights
SAN DIEGO , Feb. 28, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C...
Avidity Biosciences Announces Arthur A. Levin to Join Board of Directors and Transition to Distinguished Scientist and Strategic Leader
W. Michael Flanagan, Ph.D. named chief scientific and technical officer SAN DIEGO , Feb. 23, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to deli...
Avidity Biosciences, Inc. Announces Pricing of Upsized Public Offering of Common Stock
SAN DIEGO , Dec. 15, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C...